Abl Bio Stock Fundamentals
| 298380 Stock | KRW 24,800 450.00 1.78% |
ABL Bio fundamentals help investors to digest information that contributes to ABL Bio's financial success or failures. It also enables traders to predict the movement of ABL Stock. The fundamental analysis module provides a way to measure ABL Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ABL Bio stock.
ABL |
ABL Bio Company Shares Outstanding Analysis
ABL Bio's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current ABL Bio Shares Outstanding | 45.3 M |
Most of ABL Bio's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ABL Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, ABL Bio has 45.3 M of shares currently outstending. This is 74.91% lower than that of the Healthcare sector and 57.6% lower than that of the Biotechnology industry. The shares outstanding for all Republic of Korea stocks is 92.08% higher than that of the company.
ABL Bio Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ABL Bio's current stock value. Our valuation model uses many indicators to compare ABL Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ABL Bio competition to find correlations between indicators driving ABL Bio's intrinsic value. More Info.ABL Bio is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value ABL Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ABL Bio's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ABL Bio's earnings, one of the primary drivers of an investment's value.Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
| All Next | Launch Module |
ABL Fundamentals
| Return On Equity | 5.6 | |||
| Return On Asset | -0.31 | |||
| Operating Margin | (6.16) % | |||
| Current Valuation | 866.33 B | |||
| Shares Outstanding | 45.3 M | |||
| Shares Owned By Insiders | 31.53 % | |||
| Shares Owned By Institutions | 12.89 % | |||
| Price To Sales | 101.38 X | |||
| Revenue | 5.33 B | |||
| Gross Profit | 8.06 B | |||
| EBITDA | (53.58 B) | |||
| Net Income | (43.56 B) | |||
| Cash And Equivalents | 21.59 B | |||
| Total Debt | 72.32 M | |||
| Debt To Equity | 1.40 % | |||
| Current Ratio | 14.71 X | |||
| Cash Flow From Operations | (40.61 B) | |||
| Beta | 1.08 | |||
| Market Capitalization | 958.17 B | |||
| Total Asset | 65.45 B | |||
| Net Asset | 65.45 B |
About ABL Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ABL Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ABL Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ABL Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio is traded on Korean Securities Dealers Automated Quotations in South Korea.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABL Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the ABL Bio information on this page should be used as a complementary analysis to other ABL Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for ABL Stock analysis
When running ABL Bio's price analysis, check to measure ABL Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABL Bio is operating at the current time. Most of ABL Bio's value examination focuses on studying past and present price action to predict the probability of ABL Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABL Bio's price. Additionally, you may evaluate how the addition of ABL Bio to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |